• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What are Clinical Trials?
    • Become a Clinical Trial Volunteer
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Florida Atlantic University Creates Model to Predict Success of COVID-19 Trials

Florida Atlantic University Creates Model to Predict Success of COVID-19 Trials

August 2, 2021

Researchers at Florida Atlantic University’s College of Engineering and Computer Science have become the first to model the probability of COVID-19 trials finishing, terminating, pausing or being withdrawn using machine learning algorithms.

Their study, published in PLOS ONE, downloaded 4,441 COVID-19 trials listed on ClinicalTrials.gov for analysis. According to the study findings, their model was accurate in predicting success or failure for COVID clinical trials, and the results showed computational methods were effective at helping to understand differences between completed and ceased trials. They also showed that such models can predict the status of a COVID trial with sufficient accuracy and help in planning and reducing costs for trials.

They used four feature types (statistical features, study keywords, drug features and embedding features) to understand trial administration, eligibility, study information, criteria, drug types, study keywords and embedding features frequently used in machine learning. Using those categories, the researchers generated 693 dimensions to represent each clinical trial pulled from ClinicalTrials.gov. The study found that while drug features and study keywords were the most informative of the feature types, all were needed to accurately predict a trial’s success or failure.

The researchers said they will conduct further evaluation of features found to be associated with trial completion vs. cessation and plan to deliver interpretable results experts can use to understand what types of trials are more and less likely to make it past the finish line.

Read the full study here: https://bit.ly/3leTqXF.

    Upcoming Events

    • 05Dec

      Thriving in Clinical Research – Overcoming Common Challenges as a Site: Part 3 – Site Resourcing

    • 14Apr

      MAGI 2024: The Clinical Research Conference

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Jonathan Seltzer

      Thought Leadership: Remote Patient Monitoring Gives New View of Safety in Cardiac Clinical Trials

    • Quality_Compass-360x240.png

      Ask the Experts: Applying Quality by Design to Protocols

    • Obesity Treatment Patient

      Clinical Trials Need Greater Representation of Obese Patients, Experts Say

    • Modernize-360x240.png

      FDA IT Modernization Plan Prioritizes Data-Sharing, AI, Collaboration and More

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing